BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share capital and up to $150 million in potential milestone payments.
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company believed that the Biotheus drug “has the potential to set a new standard of care in multiple oncology indications”.
BioNTech to buy Chinese biotech firm to boost oncology strategy
German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect tumor cells in patients - Anadolu Ajansı
Germany's BioNTech to buy Chinese firm with promising cancer drug
Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its cancer drug development by agreeing to buy Chinese firm Biotheus. The Mainz-based group said in a statement on Wednesday it will pay up to $950 million,
BioNTech Acquires Biotheus to Enhance Cancer Therapies
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two companies were already co-developing an experimental antibody that targets two proteins found on cancer cells.
FierceBiotech18h
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
AOL9h
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
MM&M3h
BioNTech spends $800M upfront to pick up China-based Biotheus
BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a late ...
Business Insider5h
BioNTech to acquire Biotheus for upfront consideration of $800M
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of ...
Seeking Alpha on MSN9h
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay ...
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
BioNTech SE ADR falls Tuesday, underperforms market
The BioNTech SE ADR BNTX slid 2.22% to $106.32 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 and Dow Jones ...